Prostate cancer is the second most common cancer in men worldwide.[18 F] FDG PET/CT
imaging, a well-known and effective technique for detecting malignancies, has not been …

The purpose of this study was to compare the diagnostic performance of 18F-DCFBC
PET/CT, a first-generation 18F-labeled prostate-specific membrane antigen (PSMA) …

18 F-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) imaging in
prostate cancer is challenging because glucose utilization in well-differentiated prostate …

The role of PET imaging with11C-choline and18F-fluciclovine in evaluating patients with
prostate cancer (PCa) has become more important over the years and has been …

PSMA PET is more accurate than conventional imaging (CT/bone scan) for staging of
intermediate‐or high‐risk prostate cancer (PCa), but 5–10% of primary tumours have low …

The use of positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) in
prostate cancer depends on the phase of the disease along the natural history of this …

Purpose Prostate-specific membrane antigen (PSMA) PET/CT shows better diagnostic
performance for detection of lymph node and bone metastases as compared to conventional …

Purpose: Tumor heterogeneity and burden, which impact treatment outcome in prostate
cancer, are rarely evaluated using next-generation imaging. Experimental Design: The trial …

Purpose Current standard of care conventional imaging modalities (CIM) such as X-ray
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …

Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging
evaluation challenging. The role of imaging in prostate cancer should include diagnosis …